Clovis Oncology (NASDAQ:CLVS)

CAPS Rating: 2 out of 5

Results 1 - 10 of 10

Recs

0
Member Avatar TerryHoodSr (48.28) Submitted: 6/14/2014 10:07:26 AM : Outperform Start Price: $45.14 CLVS Score: -16.35

CLVS BUY@45 TP 83

Recs

0
Member Avatar navychop2 (23.29) Submitted: 6/11/2014 8:45:02 PM : Underperform Start Price: $43.34 CLVS Score: +12.41

Negative side affects to it's primary experimental cancer drug, burning through cash, can't find a buyer

Recs

0
Member Avatar pavlos1971 (99.54) Submitted: 6/3/2014 9:00:50 PM : Outperform Start Price: $38.23 CLVS Score: -1.69

I'll play this game of shorts, now on the long side.

Recs

0
Member Avatar Flygal5 (99.01) Submitted: 1/10/2014 8:24:18 PM : Outperform Start Price: $79.25 CLVS Score: -58.67

Pharma stock recommended by Dr. Yaron Werber citi research
Lung cancer drug
Plus two other drugs

Recs

1
Member Avatar Jordrok (98.98) Submitted: 9/30/2013 9:18:29 PM : Underperform Start Price: $60.30 CLVS Score: +53.34

No revenue yet...

Recs

0
Member Avatar getrichdietrying (82.37) Submitted: 9/25/2013 1:59:53 PM : Underperform Start Price: $63.92 CLVS Score: +56.14

Buyers are not interested at unjustified market cap valuation. sell and take the profits a great short sell now.

Recs

0
Member Avatar TMFBiologyFool (96.95) Submitted: 9/18/2013 7:00:29 PM : Underperform Start Price: $74.20 CLVS Score: +61.66

Pipeline doesn't justify $2.2 billion valuation.

Recs

0
Member Avatar HoldThatWinner (32.32) Submitted: 6/5/2013 12:12:51 PM : Outperform Start Price: $65.32 CLVS Score: -62.65

$100 Target

Recs

0
Member Avatar IBDContrarian (< 20) Submitted: 4/6/2013 1:49:18 PM : Underperform Start Price: $29.05 CLVS Score: -5.60

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 5 95 -B+ NO EARN

Recs

1
Member Avatar zzlangerhans (99.75) Submitted: 12/3/2012 5:55:04 PM : Underperform Start Price: $15.66 CLVS Score: -106.66

400M isn't an outrageous market cap for a company with 163M in cash and two early stage oncology candidates. The thing is, Clovis had the same valuation in August when topline results of their pivotal trial of their lead oncology candidate were still pending. Even though the share price ran up ahead of the crash when the trial failed and development of the lead candidate was terminated, it doesn't make sense for the stock to be running up again so quickly. I think the street is still showing overconfidence in this management team.

Results 1 - 10 of 10

Featured Broker Partners


Advertisement